@article {1478337,
	title = {Visual Acuity Outcome over Time in Non-Infectious Uveitis},
	journal = {Ocul Immunol Inflamm},
	year = {2019},
	month = {2019 Dec 10},
	pages = {1-8},
	abstract = {: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population.: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up.: Patients were a median of 41 years old, 65\% female, and 73\% white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each \&lt; .001), then remained stable, except posterior uveitis mean VA worsened to initial levels.: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.},
	issn = {1744-5078},
	doi = {10.1080/09273948.2019.1687733},
	author = {Pistilli, Maxwell and Joffe, Marshall M and Gangaputra, Sapna S and Pujari, Siddharth S and Jabs, Douglas A and Levy-Clarke, Grace A and Nussenblatt, Robert B and Rosenbaum, James T and Sen, H Nida and Suhler, Eric B and Thorne, Jennifer E and Bhatt, Nirali P and Foster, C Stephen and Begum, Hosne and Fitzgerald, Tonetta D and Dreger, Kurt A and Altaweel, Michael M and Holbrook, Janet T and Kempen, John H and Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group}
}
